

Product Data Sheet

Product Name: Eniporide hydrochloride

Cat. No.: GC35993

Chemical Properties

Cas. No. 211813-86-4

SMILES CS(=O)(C1=C(N2C=CC=C2)C=C(C)C(C(NC(N)=N)=O)=C1)=O.[H]Cl


Formula $C_{14}H_{17}ClN_4O_3S$ M.Wt 356.83

Solubility DMSO: ≥ 150 mg/mL (420.37 mM) Storage Store at $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



H-Cl

Background

Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent Na^{+}/H^{+} exchange inhibitor. Sodium Channel[1]

There is no significant effects of the Na^{+}/H^{+} exchange inhibitor eniporide on cardiac performance and high energy phosphate content in healthy pig hearts subjected to ischemia/reperfusion induced by crystalloid cardioplegic arrest[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In stage 1, the administration of 100 mg and 150 mg eniporide results in smaller infarct sizes, especially in the angioplasty group. In contrast, in stage 2 there is no difference in the enzymatic infarct size between the three groups. Overall there is no effect of eniporide on clinical outcome (death, cardiogenic shock, heart failure, life-threatening arrhythmias). However, there is a significant reduction of the incidence of heart failure in patients reperfused late (>4 h)[2].

[1]. Klass O, et al. Effect of the Na⁺/H⁺ exchange inhibitor eniporide on cardiac performance and myocardial high energy phosphates in pigs subjected to cardioplegic arrest. *Ann Thorac Surg.* 2004 Feb;77(2):658-63. [2]. Zeymer U, et al. The Na⁽⁺⁾/H⁽⁺⁾ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. *J Am Coll Cardiol.* 2001 Nov 15;38(6):1644-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA